DDR combos on the horizon at AACR22

The long-awaited proof-of-concept data for AZ’s PARP-1-selective therapy, presented at AACR, opens the door to combination strategies previously limited by hematopoietic toxicity, and could chart a path to cancer interception in people with high-risk mutations.

The 2022 meeting of the American Association for Cancer Research also featured presentations on clinical ATR inhibitors that pointed to next directions for patient selection strategies...